



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.

Tel : +91 40 23547532, Fax : +91 40 23548243

9th February, 2012

The Manager - Listing
Corporate Relationship Department
The Bombay Stock Exchange Limited
Dalal Street, Fort
Mumbai 400 001

Mr. Hari K
Vice President
M/s. National Stock Exchange of India Ltd
"Exchange Plaza", Bandra - Kurla Complex
Bandra (E) Mumbai 400 051

Scrip Code: 524816

Scrip Code: NATCOPHARM

Dear Sir,

Sub: Un-audited Financial Results for the quarter ending December, 2011
And declaration of interim dividend for the year 2011-2012

The Board of Directors of the Company at their meeting held today considered and approved the following:

01. The unaudited Results for the quarter ending 31st December, 2011 including the consolidated results, segment wise Report along with Limited Audit Review report for the said period.
02. The Board also recommended payment of an interim dividend of Rs.3/- per equity share of Rs.10/- each for the year 2011-2012.
03. The date for taking a record of its shareholders eligible for the purpose of payment of interim dividend i.e. record date is fixed as **Thursday the 23rd day of February, 2012.** The said interim dividend pay-by-date is 1th March, 2012

The promoters & promoter share holding mentioned in the un-audited results were not comparable with the previous Quarter un-audited results due to the issue of further shares under QIP and also rationalization of the promoter group share holdings.

Please find enclosed copies of the same along with Press note issued in this connection.

This is for your information and records.

Thanking you,

Yours faithfully,
for NATCO Pharma Limited

A handwritten signature in dark ink, appearing to read "M Adinarayana".

M Adinarayana
Company Secretary
GM (Legal & Corporate Affairs)

Encl: as above



Natco Pharma Limited

Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad-500 033. INDIA.
Tel : +91 40 23547532, Fax : +91 40 23548243

February 9, 2012

NATCO declares interim dividend: Sales, Profits up !!!

Hyderabad based NATCO Pharma Limited has posted an aggregate revenues of Rs. 405 Crores for the nine month period ended on 31st December, 2011, an increase of 10% over that recorded for the nine month period ended on 31st December, 2010. The company posted a net profit, after tax, of Rs. 47 Crores (Rs. 39 Crores for 2010) for the nine month period ended on 31st December.

The revenues for the quarter ended on 31st December, 2011 stand at Rs. 145 Crores as compared to Rs. 133 Crores for the three months ended on 30th September, 2011. The net profit after tax, for the same period stand at Rs. 1700 Crores as compared to Rs. 1594 lakhs.

The growth was driven by increased API sales and formulation exports.

The Board had recommended the payment of an interim dividend of Rs. 3/- per share. (2010- Rs. 2/- per share).

Forwarded for favor of publication

For NATCO PHARMA LIMITED

M. Adinarayana
M. ADINARAYANA
Company Secretary & G.M.
(Legal & Corporate Affairs)



Un-audited Financial Results (consolidated) for the three and nine months period ended 31st December, 2011

Rs. lakhs

	THREE MONTHS ENDED			YEAR TO DATE FIGURES FOR THE PERIOD ENDED		PREVIOUS ACCOUNTING YEAR (AUDITED)
	31-DEC-2011	30-SEP-2011	31-DEC-2010	31-DEC-2011	31-DEC-2010	31-MAR-2011
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	13596	12484	10703	37679	34315	44943
02. Other Operating Income	947	814	1131	2463	2462	3364
03. TOTAL INCOME	14543	13298	11834	40142	36777	48307
04. EXPENDITURE						
a) Increase / Decrease in Stock-in-Trade and work-in-progress	252	-67	-196	117	-692	-1148
b) Consumption of Raw Materials	4617	4262	4181	13289	14529	18276
c) Purchase of traded goods	293	588	407	1222	1036	1672
d) Employees Cost	2049	1705	1590	5601	4854	6407
e) Depreciation	408	402	330	1212	1073	1474
f) Other Expenditure	4217	3803	3427	11183	9829	13657
g) TOTAL	11836	10693	9739	32624	30629	40338
05. Profit from Operations before other income, interest	2707	2605	2095	7518	6148	7969
06. Other Income	35	156	26	308	90	135
07. Interest	581	612	366	1741	1175	1576
08. Less : Minority Interest	-43	-28	-94	-100	-129	-144
09. Profit / (Loss) from ordinary activities before tax, after minority interest	2204	2177	1849	6185	5192	6672
10. Tax expense, including deferred tax	504	583	477	1489	1279	1321
11. Net Profit / Loss (-) from ordinary activities after tax	1700	1594	1372	4696	3913	5351
12. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	2815	2815	3115	2815	2815
13. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year	-	-	-	-	-	32429
14. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.)	5.91/5.91	5.66/5.66	4.87/4.87	16.56/16.56	13.90/13.90	19.01/19.01
15. Public Shareholding:						
a) Number of Shares	13,389,871	10,383,626	10,502,055	13,389,871	10,502,055	10,459,455
b) Percentage of Shareholding	42.99	36.89	37.31	42.99	37.31	37.16
16. Promoters and Promoter Group Shareholding	-	1,050,000	1,050,000	-	1,050,000	1,050,000
a) Pledged / Encumbered - No. of shares	-	5.91	5.95	-	5.95	5.94
Percentage (as a % of the total shareholding of promoter and promoter group)	-	3.73	3.73	-	3.73	3.73
Percentage (as a % of the total share capital of the company)	-	-	-	-	-	-
b) Non - encumbered - No. of shares	17,758,081	16,714,326	16,595,897	17,758,081	16,595,897	16,638,497
Percentage (as a % of the total shareholding of promoter and promoter group)	100	94.09	94.05	100	94.05	94.06
Percentage (as a % of the total share capital of the company)	57.01	59.38	58.96	57.01	58.96	59.11

The above un-audited financial results were reviewed by the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 9th February, 2012. The net sales / income from operations include sales tax of (Rs. lakhs) 311, 305, 213, 819, 641, 854 and excise duty of (Rs. lakhs) 354, 362, 234, 1039, 764, 264 respectively for the quarters ended on 31st December, 2011, 30th September, 2011 and 31st December, 2010 and for the nine months period ended on 31st December, 2011 and 2010 respectively and for the year ended on 31st March, 2011. There are no exceptional and extraordinary items to be reported for the period under review. In respect of matters referred to in the consolidated Auditors' Report for the year ended on 31st March, 2011, relating to non-accounting of minimum alternative tax credit, the company will review the position at the end of the financial year ending 31 March 2012. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Consequent to the allotment of shares made to qualified institutional buyers, there has been a change in the capital structure of the company, resulting in an increase in the paid up capital by Rs. 300 lakhs. The Board has recommended the payment of an interim dividend of Rs. 3 per share. The stand-alone results are available on the company's website www.natcopharma.co.in as well as at the Registered Office of the Company.

Dated at Hyderabad, this, the 9th day of February, 2012.
for and on behalf of the Board of Directors,
NATCO Pharma Limited

Status of Investor Complaints as at 31st December, 2011

Pending as on 01-10-2011	N4
Resolved during the quarter	15
Resolved during the quarter	15
Pending as on 31-12-2011	N1

V.C. Nannapaneni
Chairman & Managing Director

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 033.



Un-audited Financial Results for the three and nine months period ended 31st December, 2011

Rs. lakhs

	THREE MONTHS ENDED (REVIEWED)			YEAR TO DATE FIGURES FOR THE PERIOD ENDED (REVIEWED)		PREVIOUS ACCOUNTING YEAR
	31-DEC-2011	30-SEP-2011	31-DEC-2010	31-DEC-2011	31-DEC-2010	31-MAR-2011
01. Net Sales / Income from Operations (including Excise Duty & Sales Tax)	11240	10479	7968	31202	25082	33826
02. Other Operating Income	947	814	1131	2464	2453	3348
03. TOTAL INCOME	12187	11293	9099	33666	27535	37174
04. EXPENDITURE						
a) Increase / Decrease in Stock-in-Trade and work-in-progress	252	-67	-196	117	-692	-1148
b) Consumption of Raw Materials	2686	2662	2179	8356	7303	9742
c) Purchase of traded goods	293	588	407	1222	1036	1672
d) Employees Cost	1706	1510	1276	4672	3888	5112
e) Depreciation	406	378	322	1162	1027	1435
f) Other Expenditure	4021	3597	3097	10542	8965	12616
g) TOTAL	9364	8668	7085	26071	21527	29429
05. Profit from Operations before other income, interest	2823	2625	2014	7595	6008	7745
06. Other Income	24	156	26	285	87	72
07. Interest	561	595	345	1687	1107	1419
08. Profit / (Loss) from ordinary activities before tax	2286	2186	1695	6193	4988	6398
09. Tax expense, including deferred tax	504	583	455	1432	1232	1186
10. Net Profit / Loss (-) from ordinary activities after tax	1782	1603	1240	4761	3756	5212
11. Paid-up Equity Share Capital (each share of Rs. 10/- face value)	3115	2815	2815	3115	2815	2815
12. Reserves excluding revaluation reserves as per Balance Sheet of previous accounting year						31876
13. Earnings per share - Basic and diluted EPS before and after extraordinary item (Rs.)	6.19 6.19	5.69 5.69	4.41 4.41	16.79 16.79	13.34 13.34	18.52 18.52
14. Public Shareholding:						
a) Number of Shares	13,389,871	10,383,626	10,502,055	13,389,871	10,502,055	10,459,455
b) Percentage of Shareholding	42.99	36.89	37.31	42.99	37.31	37.16
15. Promoters and Promoter Group Shareholding						
a) Pledged / Encumbered - No. of shares	-	1,050,000	1,050,000	-	1,050,000	1,050,000
Percentage (as a % of the total shareholding of promoter and promoter group)	-	5.91	5.95	-	5.95	5.94
Percentage (as a % of the total share capital of the company)	-	3.73	3.73	-	3.73	3.73
b) Non - encumbered - No. of shares	17,758,081	16,714,326	16,595,897	17,758,081	16,595,897	16,638,497
Percentage (as a % of the total shareholding of promoter and promoter group)	100	94.09	94.05	100	94.05	94.06
Percentage (as a % of the total share capital of the company)	57.01	59.38	58.96	57.01	58.96	59.11

The above un-audited financial results were reviewed by the statutory auditors of the Company, the Audit Committee and approved by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 9th February, 2012. The net sales / income from operations include sales tax of (Rs. lakhs) 311, 305, 213, 819, 641, 854 and excise duty of (Rs. lakhs) 107, 61, 41, 225, 148, 264 and other operating income includes excise rebate of (Rs. Lakhs) 155, 172, 75, 527, 368, 550 respectively for the quarters ended on 31st December, 2011, 30th September, 2011 and 31st December, 2010 and for the nine months period ended on 31st December, 2011 and 2010 respectively and for the year ended on 31st March, 2011. There are no exceptional and extraordinary items to be reported for the period under review. In respect of matters referred to in the limited review report by the Auditors relating to non-accounting of minimum alternative tax credit, the company will review the position at the end of the financial year ending 31 March 2012. Figures for the previous period(s) have been re-arranged / re-grouped wherever necessary. Consequent to the allotment of shares made to qualified institutional buyers, there has been a change in the capital structure of the company, resulting in an increase in the paid up capital by Rs. 300 lakhs. The Board has recommended the payment of an interim dividend of Rs. 3 per share.

Dated at Hyderabad, this, the 9th day of February, 2012,
for and on behalf of the Board of Directors,
NATCO Pharma Limited

V.C. Nannapaneni
Chairman & Managing Director

Status of Investor Complaints as at 31st December, 2011

Pending as on 01-10-2011	Nil
Resolved during the quarter	15
Pending as on 31-12-2011	Nil




Report of segment wise revenue, Results and Capital Employed, (Un-audited) under Clause 41 of the Listing Agreement, for the quarter and nine months period ended on 31st December, 2011

Rs. lakhs

	THREE MONTHS ENDED (REVIEWED)			YEAR TO DATE FIGURES FOR THE PERIOD ENDED (REVIEWED)		PREVIOUS ACCOUNTING YEAR (UN- AUDITED, UN- REVIEWED)
	31-DEC- 2011	30-SEP-2011	31-DEC- 2010	31-DEC-2011	31-DEC-2010	31-MAR-2011
01. Segment Revenue (Net Sales / Income (including Excise Duty & Sales Tax)						
a) Bulk Chemicals	4298	4114	2844	12681	8600	12012
b) Formulations	7546	6828	5461	19820	17646	23211
c) Job Work	228	233	349	691	798	1098
d) Unallocated (Others)	743	678	808	2059	1679	2203
Total	12817	11853	9462	35251	28723	38524
Less : Inter-segment Revenue	608	403	337	1300	1101	1350
Net Sales / Income from Operations	12208	11450	9125	33951	27622	37174
02. Segment Results : Profit (+)/Loss (-) before tax and interest						
a) Bulk Chemicals	703	937	243	2423	788	1458
b) Formulations	2872	2799	2269	7883	7173	11001
c) Job Work	186	179	254	558	630	872
d) Unallocated (Others)	743	-1133	505	889	1375	-5513
Total	4504	2782	3271	11753	9966	7818
Less : a) Interest	562	596	345	1687	1107	1420
b) Other allocable expenditure net of unallocable income	1656		1231	3872	3871	
Total Profit Before Tax	2286	2186	1695	6193	4988	6398
03. Capital Employed (Segment Assets - Segment Liabilities)						
a) Bulk Chemicals	26240	23233	19247	26240	19247	15055
b) Formulations	27546	23914	20127	27546	20127	23390
c) Job Work	184	150	367	184	367	216
e) Unallocated (Others)	-7576	-9527	-6046	-7576	-6046	-3971
Total	46394	37770	33695	46394	33695	34690

The above report of segment wise revenue, results and capital employed for the quarter and period ended on 31st December, 2011 was considered and taken on record by the Board of Directors at a meeting held at Hyderabad on Thursday, the 9th February, 2012.

Dated at Hyderabad, this, the 9th day of February, 2012.
for and on behalf of the Board of Directors,
NATCO Pharma Limited


V.C. Nannapaneni
Chairman & Managing Director

Regd. Office: NATCO House, Road # 2, Banjara Hills, Hyderabad : 500 033.